Redeye provides its preview of Integrum’s Q1 2025 report, due on Monday, September 1.
Redeye comments on Active Biotech's second quarter report.
Redeye views InfraCom’s Q2 2025 results as mixed, with a declining top line contrasted by rising EBI...
Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...
Redeye has updated its estimates and valuation for Sleep Cycle following the Q2 2025 report, which w...
Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y, which wa...
* Net acquistions in H2'25 * Buy-backs supportive for the share * 2025e P/CEPS 11x vs.
Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the qua...
* Gross margin at 45% (40%) * SaaS supports margins and outlook * Trading at ~11-9x EV/EBITA for '26...
* Q2 NAV in line with ABGSCe * Key highlights: Safe Life transaction and buybacks * Discount still w...
Redeye provides a research update following the Q2 report recently published by Initiator Pharma.
* Sales +4% and adj. EBIT -47% vs ABGSCe * Weak demand in consulting and recruitment market * Consen...
Solteq’s Q2 result was below our expectations. Retail & Commerce was decent, while Utilities remaine...
* Sales -39% vs. ABGSCe, EBIT SEK 5m vs. ABGSCe 16m * Weak Q2 due to inventory build-up following st...
